SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Tularik Inc. (TLRK)
An SI Board Since October 1999
Posts SubjectMarks Bans Symbol
598 27 0 TLRK
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
148It is becoming painful averaging down my position against these guys. Someone imopgcw-4/8/2002
147three posters on T67, two phase II one phase I. two posters T607. can't anscaram(o)uche-4/3/2002
146discovered 22 new oncogenes T67 going forward liver cancer, pending end of phasscaram(o)uche-4/3/2002
145I've watched carefully at the last three closes. These guys are desperatelyscaram(o)uche-4/1/2002
144big block..... look at this bail/shorting, going into ASCO. If data is good, iscaram(o)uche-4/1/2002
143Tularik to Present at Banc of America Securities Healthcare Conference Businessmopgcw-3/28/2002
142Short interest continued up for March, at 2,134,889 shares. (eom)scaram(o)uche-3/27/2002
1418-K....... Item 4. Changes in Registrant’s Certifying Accountants On March 1scaram(o)uche-3/19/2002
140Mol Cell 2002 Feb;9(2):401-10 TNF-Induced Recruitment and Activation of the IKscaram(o)uche-3/8/2002
139J Biol Chem 2002 Mar 4; [epub ahead of print] T0070907, A selective ligand forscaram(o)uche-3/8/2002
138With ASCO coming, it takes guts to short this aggressively. I've long consiscaram(o)uche-3/7/2002
137Thanks. Flavor like that is invaluable, when it adds up. Today's move.....scaram(o)uche-3/6/2002
136Quite a move today on decent volume. Maybe the stock was just making a bit of aquidditch-3/6/2002
135Tularik to Present at Lehman Brothers 5th Annual Healthcare Conference SOUTH SANmopgcw-2/27/2002
134GS: We are initiating coverage of Tularik with a Market Outperformer rating. Tmopgcw-2/15/2002
133MARLBOROUGH, Mass.--(BW HealthWire)--Feb. 6, 2002--Cetek Corporation announced tnigel bates-2/6/2002
132Tularik Announces Departure of Andrew J. Perlman, EVP SOUTH SAN FRANCISCO, Calimopgcw-2/5/2002
131TLRK added to Valueline coverage. Quite a bullish writeup. georgemopgcw-1/27/2002
130"">> has enrolled << Correct, which means that they are NOMiljenko Zuanic-1/17/2002
129>> has enrolled << Correct, which means that they are NOT doing dosscaram(o)uche-1/16/2002
128You guys are confusing me. From HnQ: My paraphrase re: T67: P2 in hepatocellukeokalani'nui-1/16/2002
127>> still doing doses intensification studies << On T67? Do you meascaram(o)uche-1/16/2002
126<<If I get them, I'll post them. >> By PM, few hours before relMiljenko Zuanic-1/16/2002
125If I get them, I'll post them. The presentation was cut and dry, professionscaram(o)uche-1/16/2002
124T67 P2 results to be at '02 ASCO. Any early peeks would be appreciated. Wikeokalani'nui-1/16/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News